Publication|Articles|December 2, 2025
Supplements and Featured Publications
- 2025 Year in Review: Idiopathic Pulmonary Fibrosis
2025 Year in Review: Idiopathic Pulmonary Fibrosis
Key Takeaways
This year in review of 2025 milestones in idiopathic pulmonary fibrosis (IPF) features coverage of research on therapeutic efficacy presented at the American Thoracic Society 2025 International Conference in May, as well as studies on lung function thresholds and mortality predictors. It also includes interviews with Marilyn Glassberg, MD, on the significance of early diagnosis of IPF, and Justin M. Oldham, MD, PhD, MS, on first-line treatment choices for the chronic lung disease.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
3
United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF
4
HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD
5

